A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Clinical trial NCT07218380 · RECRUITING

Trial details

NCT number: NCT07218380
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Transitional Cell Urinary Bladder Neoplasms Neoplasm Metastasis

Start date: 2025-12-12
Primary completion: 2029-10-01
Enrollment: 450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.